1. Home
  2. SUPN vs PENN Comparison

SUPN vs PENN Comparison

Compare SUPN & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • PENN
  • Stock Information
  • Founded
  • SUPN 2005
  • PENN 1972
  • Country
  • SUPN United States
  • PENN United States
  • Employees
  • SUPN N/A
  • PENN N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • PENN Hotels/Resorts
  • Sector
  • SUPN Health Care
  • PENN Consumer Discretionary
  • Exchange
  • SUPN Nasdaq
  • PENN Nasdaq
  • Market Cap
  • SUPN 2.6B
  • PENN 2.8B
  • IPO Year
  • SUPN 2012
  • PENN 1994
  • Fundamental
  • Price
  • SUPN $47.92
  • PENN $18.17
  • Analyst Decision
  • SUPN Buy
  • PENN Buy
  • Analyst Count
  • SUPN 2
  • PENN 19
  • Target Price
  • SUPN $51.50
  • PENN $22.89
  • AVG Volume (30 Days)
  • SUPN 682.2K
  • PENN 3.2M
  • Earning Date
  • SUPN 11-03-2025
  • PENN 11-06-2025
  • Dividend Yield
  • SUPN N/A
  • PENN N/A
  • EPS Growth
  • SUPN 1411.53
  • PENN N/A
  • EPS
  • SUPN 1.14
  • PENN N/A
  • Revenue
  • SUPN $665,125,000.00
  • PENN $6,745,700,000.00
  • Revenue This Year
  • SUPN $6.71
  • PENN $8.37
  • Revenue Next Year
  • SUPN $19.74
  • PENN $5.54
  • P/E Ratio
  • SUPN $42.23
  • PENN N/A
  • Revenue Growth
  • SUPN 5.55
  • PENN 7.33
  • 52 Week Low
  • SUPN $29.16
  • PENN $13.25
  • 52 Week High
  • SUPN $49.66
  • PENN $23.08
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 66.02
  • PENN 39.13
  • Support Level
  • SUPN $47.34
  • PENN $18.89
  • Resistance Level
  • SUPN $49.66
  • PENN $19.43
  • Average True Range (ATR)
  • SUPN 1.23
  • PENN 0.48
  • MACD
  • SUPN -0.08
  • PENN -0.18
  • Stochastic Oscillator
  • SUPN 66.70
  • PENN 1.38

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About PENN PENN Entertainment Inc.

Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.

Share on Social Networks: